Terms: = Prostate cancer AND CBFB, PEBP2B, 865, ENSG00000067955, Q13951 AND Treatment
27 results:
1. Development of a prognostic model for long-term survival of young patients with bladder cancer: a retrospective analysis of the SEER Database.
Guo L; Liu L; Liu Y; Yang T; Wang G; Liu J; Li S; Cai J
BMJ Open; 2024 Mar; 14(3):e080092. PubMed ID: 38458812
[TBL] [Abstract] [Full Text] [Related]
2. Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer.
He W; Zhang F; Jiang F; Liu H; Wang G
BMC Urol; 2022 Nov; 22(1):195. PubMed ID: 36434610
[TBL] [Abstract] [Full Text] [Related]
3. High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer.
Liu Z; Zhang JY; Yang YJ; Chang K; Wang QF; Kong YY; Dai B
Asian J Androl; 2022; 24(2):147-153. PubMed ID: 34755700
[TBL] [Abstract] [Full Text] [Related]
4. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract] [Full Text] [Related]
5. Trends for Stage and Grade Group of prostate cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract] [Full Text] [Related]
6. Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy.
Prabhu N; Kapur N; Catalona W; Leikin R; Helenowski I; Jovanovich B; Gurley M; Okwuosa TM; Kuzel TM
Urol Oncol; 2021 Feb; 39(2):130.e9-130.e15. PubMed ID: 33132024
[TBL] [Abstract] [Full Text] [Related]
7. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
Liu J; Prager-van der Smissen WJC; Collée JM; Bolla MK; Wang Q; Michailidou K; Dennis J; Ahearn TU; Aittomäki K; Ambrosone CB; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Augustinsson A; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bernstein L; Bogdanova NV; Bogdanova-Markov N; Bojesen SE; Brauch H; Brenner H; Briceno I; Brucker SY; Brüning T; Burwinkel B; Cai Q; Cai H; Campa D; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Choi JY; Christiaens M; Clarke CL; ; Couch FJ; Czene K; Daly MB; Devilee P; Dos-Santos-Silva I; Dwek M; Eccles DM; Eliassen AH; Fasching PA; Figueroa J; Flyger H; Fritschi L; Gago-Dominguez M; Gapstur SM; García-Closas M; García-Sáenz JA; Gaudet MM; Giles GG; Goldberg MS; Goldgar DE; Guénel P; Haiman CA; Håkansson N; Hall P; Harrington PA; Hart SN; Hartman M; Hillemanns P; Hopper JL; Hou MF; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakimovska M; Jakubowska A; John EM; Kaaks R; Kang D; Keeman R; Khusnutdinova E; Kim SW; Kraft P; Kristensen VN; Kurian AW; Le Marchand L; Li J; Lindblom A; Lophatananon A; Luben RN; Lubiński J; Mannermaa A; Manoochehri M; Manoukian S; Margolin S; Mariapun S; Matsuo K; Maurer T; Mavroudis D; Meindl A; Menon U; Milne RL; Muir K; Mulligan AM; Neuhausen SL; Nevanlinna H; Offit K; Olopade OI; Olson JE; Olsson H; Orr N; Park SK; Peterlongo P; Peto J; Plaseska-Karanfilska D; Presneau N; Rack B; Rau-Murthy R; Rennert G; Rennert HS; Rhenius V; Romero A; Ruebner M; Saloustros E; Schmutzler RK; Schneeweiss A; Scott C; Shah M; Shen CY; Shu XO; Simard J; Sohn C; Southey MC; Spinelli JJ; Tamimi RM; Tapper WJ; Teo SH; Terry MB; Torres D; Truong T; Untch M; Vachon CM; van Asperen CJ; Wolk A; Yamaji T; Zheng W; Ziogas A; Ziv E; Torres-Mejía G; Dörk T; Swerdlow AJ; Hamann U; Schmidt MK; Dunning AM; Pharoah PDP; Easton DF; Hooning MJ; Martens JWM; Hollestelle A
Sci Rep; 2020 Jun; 10(1):9688. PubMed ID: 32546843
[TBL] [Abstract] [Full Text] [Related]
8. Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.
van Gelder T; Mulhern B; Schoormans D; Husson O; De Abreu Lourenço R
Qual Life Res; 2020 Jun; 29(6):1483-1494. PubMed ID: 31938965
[TBL] [Abstract] [Full Text] [Related]
9. Examining Public Communication About Kidney cancer on Twitter.
Sedrak MS; Salgia MM; Decat Bergerot C; Ashing-Giwa K; Cotta BN; Adashek JJ; Dizman N; Wong AR; Pal SK; Bergerot PG
JCO Clin Cancer Inform; 2019 Mar; 3():1-6. PubMed ID: 30860867
[TBL] [Abstract] [Full Text] [Related]
10. Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy.
Wong NC; Lam C; Patterson L; Shayegan B
BJU Int; 2019 Jan; 123(1):51-57. PubMed ID: 29969172
[TBL] [Abstract] [Full Text] [Related]
11. Intraductal Carcinoma of the prostate on Diagnostic Needle Biopsy Predicts prostate cancer Mortality: A Population-Based Study.
Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
Prostate; 2017 Jun; 77(8):859-865. PubMed ID: 28240424
[TBL] [Abstract] [Full Text] [Related]
12. Multinational Prospective Study of Patient-Reported Outcomes After prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID; Crociani C; McLaughlin WP; Mantz CA; Finkelstein SE; Suy S; Collins SP; Garin O; Ferrer M; Hamstra DA; Spratt DE
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):770-777. PubMed ID: 27663760
[TBL] [Abstract] [Full Text] [Related]
13. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract] [Full Text] [Related]
14. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant prostate cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract] [Full Text] [Related]
15. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract] [Full Text] [Related]
16. High-Dose Robotic Stereotactic Body Radiotherapy in the treatment of Patients With prostate cancer: Preliminary Results in 26 Patients.
Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
[TBL] [Abstract] [Full Text] [Related]
17. Oncologic outcomes after minimally invasive radical prostatectomy in patients with seminal vesicle invasion (pT3b) without adjuvant therapy.
Forgues A; Rozet F; Audenet F; Ouzzane A; Sanchez-Salas R; Barret E; Galiano M; Prapotnich D; Cathelineau X
World J Urol; 2014 Apr; 32(2):519-24. PubMed ID: 23881352
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Lin GW; Yao XD; Ye DW; Zhu Y; Zhang SL; Dai B; Zhang HL; Shen YJ; Ma CG
Asian J Androl; 2012 Sep; 14(5):732-7. PubMed ID: 22902911
[TBL] [Abstract] [Full Text] [Related]
19. Killed but metabolically active vaccines.
Dubensky TW; Skoble J; Lauer P; Brockstedt DG
Curr Opin Biotechnol; 2012 Dec; 23(6):917-23. PubMed ID: 22608846
[TBL] [Abstract] [Full Text] [Related]
20. Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects.
Lee S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2010 Dec; 32(14):2496-501. PubMed ID: 21353117
[TBL] [Abstract] [Full Text] [Related]
[Next]
